Incorporated in March 1984 as a Private Limited Company, Highnoon was born in the historical city of Lahore, Pakistan and became a Public Limited Company by 1995.
Right from its inception, Highnoon formed alliances with some of the best-known research houses in the global pharmaceutical industry, helping the company to always continuously progress through both the quality and variety of our products and services.
Our ultimate goal is to enrich the health of patients by empowering the health care professionals with high-quality pharmaceutical products. At Highnoon, we believe in continuous improvement in every aspect of our business; from investing in new equipment and technology by upgrading our manufacturing facilities in compliance with ‘Current Good Manufacturing Practices (cGMP)’ to focusing on training and development of our human capital.
We pride ourselves on the thought leadership and empowering nature of work environment visible at all levels of the organization. The empowering environment in our company allows our teams to make decisions that align with our core purpose, and forms a culture that thrives on freedom for initiative and creativity. This is why Highnoon is always ahead of the curve and bringing forth world-class capabilities in marketing, sales, research & development, and manufacturing. Here’s to discovery, and to scaling new heights by seeking newer and higher challenges.
Our purpose – enriching life – inspires us and guides us to consistently deliver quality products. We enrich life by providing innovative disease management solutions.
Our responsibility is to the healthcare providers and to the patients who trust our products. We meet the expectations, and to do so, we employ the best people and invest in their continuous development; we raise our standards and challenge ourselves; we improve our processes, and we adapt new technologies.
Our purpose to enrich life requires us to expand our offering and our reach. We are committed to deepen and widen our portfolios and maximise our coverage. We seek to balance patient welfare with our financial output. We keep our costs low to reduce the disease burden on the patient and generate adequate profits for our long-term viability.
Mr. Tausif Ahmad Khan
Chairman
Our Vision
We at Highnoon Laboratories Limited understand the duties of being responsible corporate citizen and stand true to our conviction and promise to work for the betterment and prosperity of our people.
Our Mission
Our success depends on a competent and productive R & D function. Being a leading local pharmaceutical company, Highnoon has established an innovative R & D structure that encourages creativity and facilitates the accelerated development of new medicines to meet the customer needs.
Physique
Highoon Sun/Logo-Representation of 'Life', *Our Credo & Mantra
Highnoon logo represents the highest point of the Sun – Sun represents life as without it there is no life. Hence, Highnoon represents life itself.
Constant drive to be the best to serve doctors and patients and therefore, Excellence is a key physique element.
Personality
Helpful, Strong, Caring, Innovative
Helpful to solve patients problems. Strong and Daring Personality to take up Health Issues and try to find solutions.
Caring nature to genuinely help doctors serve patients.
Innovative in looking for personalised care.
Relationship
Trustworthy, Serious and Emphatic
Taking up health as a serious issue and building a relation with doctors and patients which is based on Trust
To come across as an empath who genuinely wants to solve patients problems and help them be at ease.
Culture
Better Health for Everyone, Empowering People
Belief in better health for everyone.
Passionate in empowering people (not just enabling them) to make conscious decisions on their health through technology and research.
Reflection
Determined to bring about Change in Healthcare, Solution Oriented
Determined to make people’s life healthier as we understand them better!
Taking up problems and finding solutions for patients (e.g. Pain and Palliative Care in Pakistan).
Self-Image
Scientific and Research Driven Solutions to Customers, Genuine
To come across as a scientific and research based organisation who holds itself for the highest standards of integrity.
Come across as Genuine in efforts to resolve patient’s health related issues.
leadership
Our Leadership
Dr. Adeel Abbas
Vice Chairman & CEO
Mr. Taufiq Ahmad Khan
Managing Director Curexa
Mr. Ashfaq
Chief Financial Officer
Dr. Azfar Abbas Haidrie
Chief Commercial Officer
Mr. Shahnawaz Baig
Chief Business Officer
Mr. Sajjad Hafeez
Deputy Managing Director
Mr. Zulfiqar Ali Zaidi
Director HR & Strategic Planning
Mr. Waqas Anjum
Chief Operating Officer Route2HealthOur Core Values
Perseverance
Staying true to the cause is our key to success.
Reliability
We earn trust by remaining consistent in quality.
Compassion
We are humble, empathic, and help each other grow.
Integrity
We remain honest and fair even if no one is watching.
Courage
We leap beyond our comfort zone.
Customer Focus
Enriching life is our driving force.
Our
Aspiring Values
Passion
Enriching life is our driving force.
Innovation
We constantly break new ground.
Our Quality Policy
Our quest is to lead Highnoon in achieving the benefits of Quality Management System for the manufacture and Supply of products by providing value added services that drive quality products, customer satisfaction, regulatory compliance, secure source of supply and business excellence.
Shaping
Tomorrow
Environmental Social & Governance of Highnoon stem from the founder’s vision of a healthier nation. In the role of a good corporate citizen, Highnoon is fully cognizant of its social obligations. Reaching for the declared vision Highnoon believes in a holistic approach. Highnoon’s contribution is vital in serving the needs of the community that are economically and socially viable, this encompasses fine areas like health, disaster (flood, earthquakes), promoting art & culture, valuing sports, supporting education, and social causes for the well-being of the society. Over the years Highnoon has been actively supporting such noble causes.
1985
1986
1987
1989
1990
1993
1994
Company Entered in export business
1996
An ACE inhibitor, Tanatril (Imidapril) 10mg tablets, a product of Mitsubishi Tanabe, Japan
1997
An antihistamine drug, Senergy-OD (Loratadine) tablets and oral suspension
1998
2000
Introduced recombinant vaccine for the treatment of Hepatitis-B with the brand name Heprovac-B
2001
2002
A rheumatic painkiller drug, Rheuoxib (Celecoxib) Capsules
2003
Received 5th best Annual Report 2002 award from Joint Committee of ICAP and ICMAP.
2004
- An antiulcerant drug, Rabecid (Rabeprazole Sodium) enteric coated tablets
- A broad spectrum antibiotic, Termibex (Co-Amoxiclav) tablets and dry suspensions
- An antihistamine drug, Kestine (Ebastine) in liquid form, a product of Almirall Prodesfarma, Spain
- An antiulcerant drug, Ulsanic (Sucralfate) suspension, a product of Chugai Pharma, Japan
- Compiled Bioequivalence assessment of enteric coated aspirin brands (Nu-sales with its brand Loprin) after a single oral dose of 150mg in healthy male adults. Published from France and can be viewed online at akademisyen.com/dergiler/impact.asp
- Acquired brand Tres Orix Forte from its principal Almirall Prodesfarma, Spain for the territories of Pakistan and Kenya
- Patent Office, UK grants Highnoon Laboratories Limited, the certificate of patent for its novel research oral rehydration formulation “Peptilose”
2005
A blood anticoagulant drug, Pidogrel (Clopidogrel) and Pidogrel (Clopidogrel + Aspirin) combination tablets
2006
- A painkiller drug, Airtal (Aceclofenac) tablets, a product of Almirall Prodesfarma, Spain
- A broad spectrum antibiotic, Cyrocin (Ciprofloxacin HCl) tablets
- A broad spectrum antibiotic, Evacef (Cefadroxil Monohydrate) drops and tablets, a line extension
2008
2009
- Silver Jubilee Celebration year
- Commenced direct marketing in Vietnam and Sri Lanka
- Under the umbrella of Corporate Social Responsibility, Highnoon started donating Feripro to Pakistan Thalassemia Welfare Society
- Signed business partnership agreement with Cipla, India
- An antimalarial drug, Artecxin (Artemether+Lumefantrine) and Artecxin Forte (Artemether+Lumefantrine) tablets
- A novel gastroprokinetic drug, Cidine (CInitapride) tablets, a product of Almirall Prodesfarma, Spain
- A broad spectrum antibiotic, Efix (Cefixime) Capsules and dry suspension
- An Antiasthma & COPD product, Combivair (Budesonide + Formoterol Fumarate) dry powder inhaler capsules, a product of Cipla, India
- An Antiasthma & COPD product, Tiovair (Tiotropium) dry powder inhaler capsules, a product of Cipla, India
- An Antiasthma & COPD product, Tiovair F (Tiotropium + Formoterol Fumarate) dry powder inhaler capsules, a product of Cipla, India
2010
A disease modifying agent for Osteoarthritis, Artrodar (Diacerein) Capsule, a product of TRB Chemedica, Switzerland
2011
- Signed agreement with Acino Pharma, Switzerland, for Oncology products
- Another UV-Spectrometer (Shimadzo, Japan) was added in the laboratory of Quality Control
- Provided iPADs to Managers of a team for e-communication with doctors
- Started Sales Effectiveness Office in major cities of Pakistan i.e., Lahore, Karachi and Rawalpindi
- Launched, Electronic Territory Management System
- An antimalarial drug, Artecxin (Artemether & Lumefantrine), Artecxin Forte (Artemether & Lumefantrine) dispersible tablets and Artecxin Plus (Artemether & Lumefantrine) tablets
- An antihypertensive drug, Nebix (Nebivolol) tablets
- An antidiabetic drug, Tagip (Sitagliptin) tablets and Tagipmet (Sitagliptin + Metformin HCL) tablets
- An antiasthma drug, Ventomax (Montelukast Sodium) tablets
2012
- Best Performance Award bestowed to Highnoon Laboratories Limited by Honorable President of Pakistan
- Upgradation of Product Development Laboratory
- Upgradation of Hormonal Product Manufacturing Facility
- Completion of Walk-In Stability Chambers
- Upgradation of Solid Dosage Area
- Upgradation of Quality Operations Laboratory and Equipment
- Completion of dedicated Consumer Health Products Manufacturing Facility
2013
- An antiulcerant drug, Axesom (Esomeperazole) capsules
- An anticough drug, Prospan (Ivy Extract) Syrup, a product of Engelhard, Germany
2014
- An antiasthma drug, Foracort (Formoterol Fumarate + Budesonide) HFA inhaler, a product of Cipla, India
- A broad spectrum antibiotic, Cyrocin (Ciprofloxacin) Suspension, a line extension
- An antihypertensive drug, Misar (Telmisartan) tablets
- A cardioprotective drug, Myogard (herbal combination) tablets
2015
- An antiasthma drug, Foracort (Formoterol Fumarate + Budesonide) HFA inhaler, a product of Cipla, India
- A broad spectrum antibiotic, Cyrocin (Ciprofloxacin) Suspension, a line extension
- An antihypertensive drug, Misar (Telmisartan) tablets
- A cardioprotective drug, Myogard (herbal combination) tablets
2016
- An oral anti-diabetic medicine, XORMET XR
- A new product in respiratory segment, Sprahaler Respules